BRAF-mutated malignant melanoma with chondrosarcomatous differentiation in inguinal nodal metastasis

被引：1

作者：

Abbati, Francesca ^{[1
]}

Altimari, Annalisa ^{[2
]}

Corti, Barbara ^{[3
]}

Dika, Emi ^{[4
]}

Sperandi, Francesca ^{[1
]}

Melotti, Barbara ^{[5
]}

机构：

[1] Univ Bologna, IRCCS Azienda Osped, Dept Med Oncol, Bologna, Italy

[2] Univ Bologna, IRCCS Azienda Osped, Lab Oncol Mol Pathol, Bologna, Italy

[3] Univ Bologna, St Orsola Malpighi Hosp, Dept Diagnost Med & Prevent, Pathol Unit, Bologna, Italy

[4] Univ Bologna, Dept Expt Diagnost & Specialty Med, Dermatol, Bologna, Italy

[5] IRCCS Azienda Osped Univ St Orsola, Malpighi Hosp, Dept Med Oncol, Bologna, Italy

来源：

CLINICAL CASE REPORTS | 2021年 / 9卷 / 04期

关键词：

BRAF mutation; chondrosarcomatous differentiation; melanoma;

D O I：

10.1002/ccr3.3982

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report the case of a young woman who developed metastatic melanoma in the inguinal nodal region, which acquired chondrosarcomatous differentiation and preserved the BRAF mutation found in the primary tumor. The patient was treated with a BRAF/MEK inhibitor combination therapy (dabrafenib/trametinib), which was demonstrated to be effective and well-tolerated.

引用

页码：2200 / 2204

页数：5

共 50 条

[1] MEK Inhibition in BRAF-Mutated Melanoma
MacKenzie, Alex
Boycott, Kym
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (14): : 1364 - 1365
[2] Vemurafenib and cobimetinib in BRAF-mutated melanoma
Rahman, Ahmadur
[J]. LANCET ONCOLOGY, 2014, 15 (12): : E535 - E535
[3] Radiosensitizing effect of BRAF inhibitors in BRAF-mutated melanoma
Hecht, M.
Grabenbauer, M.
Fietkau, R.
Distel, L. V.
Heinzerling, L.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 35 - 35
[4] Development of encorafenib for BRAF-mutated advanced melanoma
Koelblinger, Peter
Thuerigen, Olaf
Dummer, Reinhard
[J]. CURRENT OPINION IN ONCOLOGY, 2018, 30 (02) : 125 - 133
[5] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
Larkin, James
Ascierto, Paolo A.
Dreno, Brigitte
Atkinson, Victoria
Liszkay, Gabriella
Maio, Michele
Mandala, Mario
Demidov, Lev
Stroyakovskiy, Daniil
Thomas, Luc
de la Cruz-Merino, Luis
Dutriaux, Caroline
Garbe, Claus
Sovak, Mika A.
Chang, Ilsung
Choong, Nicholas
Hack, Stephen P.
McArthur, Grant A.
Ribas, Antoni
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20): : 1867 - 1876
[6] Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Spagnolo, Francesco
Ghiorzo, Paola
Queirolo, Paola
[J]. ONCOTARGET, 2014, 5 (21) : 10206 - 10221
[7] Treatment of BRAF-mutated advanced cutaneous melanoma
Van Anh Trinh
You, Yan
Hwu, Wen-Jen
[J]. CHINESE CLINICAL ONCOLOGY, 2014, 3 (03)
[8] The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
Liu, Xiao
Wu, Jinfeng
Qin, Haihong
Xu, Jinhua
[J]. TARGETED ONCOLOGY, 2018, 13 (04) : 437 - 446
[9] The Development of Vemurafenib for BRAF-mutated, Metastatic Melanoma
Borellini, F.
[J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S74 - S74
[10] Dabrafenib and Trametinib for BRAF-Mutated Conjunctival Melanoma
Kim, Jenna May
Weiss, Sarah
Sinard, John H.
Pointdujour-Lim, Renelle
[J]. OCULAR ONCOLOGY AND PATHOLOGY, 2020, 6 (01) : 35 - 38

← 1 2 3 4 5 →